Sedation, analgesia & anxiolysis: why characterising drug properties matters

Why characterising drug properties matters

When we select drugs for premedication and sedation, it is easy to think in shorthand. "That's a sedative." The problem is that this label is imprecise, and imprecision at this stage of an anaesthetic has real consequences.

Most of the drugs we reach for in veterinary anaesthesia do not do just one thing. They produce a mix of effects - some desirable for a given patient, some neutral, and some potentially counterproductive. A drug that provides excellent sedation may offer very little analgesia. A drug that produces profound analgesia may carry a meaningful risk of dysphoria/disinhibition in certain patients. Understanding the specific pharmacological properties of each drug - and how those properties map onto what your patient actually needs - is the foundation of rational drug selection.

There are four properties worth understanding clearly: sedation, anxiolysis, analgesia, and dysphoria/disinhibition potential. These are not synonyms, they do not reliably flow together, and confusing them can lead to patients that are heavily sedated but still in pain, or animals that are calm on the outside but experiencing something far more distressing internally.

Sedation

Sedation refers to a reduction in awareness and responsiveness to the environment. A sedated animal is less alert, less reactive, and generally easier to handle. Sedation operates primarily through depression of the central nervous system - reducing arousal and blunting the normal processing of sensory input.

It is worth being clear about what sedation does not do. Sedation does not remove pain. A deeply sedated patient can still be experiencing significant nociceptive input - they simply lack the motor capacity or cortical awareness to respond to it in the way an unsedated animal would. This is one of the most important distinctions in perioperative pharmacology.

Sedation also does not reliably reduce anxiety, which may seem counterintuitive. A sufficiently sedated animal cannot express anxiety, but that is not the same thing as the anxiety no longer existing. This distinction becomes clinically relevant when you start to reduce sedative depth - for example, during a prolonged recovery - and find that the anxiety re-emerges as the drug wears off.

Drugs that produce reliable and useful sedation in clinical veterinary anaesthesia include acepromazine (ACP), the alpha-2 adrenoreceptor agonists (medetomidine and dexmedetomidine), and at moderate to higher doses, most opioids. Among opioids, morphine, methadone, and fentanyl all produce clinically relevant sedation, though the degree varies considerably between individuals and species.

Anxiolysis

Anxiolysis is the reduction of anxiety - a distinct neurobiological process from sedation. An anxiolytic drug reduces the emotional and physiological response to perceived threat or uncertainty. A truly anxiolytic drug can calm a patient without necessarily making them drowsy, and in some contexts, this is precisely what is needed.

The distinction matters because anxiety itself has physiological consequences. A highly anxious patient arriving for induction has elevated circulating catecholamines, increased heart rate and blood pressure, and a sensitised stress response. Anxiety also influences how animals experience pain - anxious patients typically have lower pain thresholds and experience nociceptive stimuli more intensely. Addressing anxiety is not just about making an animal easier to handle; it is about setting the physiological context for everything that follows.

True anxiolysis in the pharmacological sense is mediated primarily through GABAergic pathways - the benzodiazepines (midazolam, diazepam) are the clearest example of drugs that produce genuine anxiolysis with relatively modest sedative effect at clinical doses. The alpha-2 agonists also produce meaningful anxiolysis, which likely contributes to their clinical effectiveness in anxious or fractious animals beyond just their sedative properties. ACP, perhaps surprisingly, does not reliably produce anxiolysis despite being commonly thought of as a "calming" drug - its apparent calming effect is sedation rather than a reduction in the anxious state itself. Opioids, while valuable for their sedative and analgesic properties, do not contribute meaningfully to anxiolysis - an important consideration when building protocols for genuinely anxious patients.

Analgesia

Analgesia is the reduction of pain perception. In strict pharmacological terms, it refers to the absence of, or reduction in, the conscious experience of a painful stimulus, without necessarily producing loss of consciousness.

This is a core requirement for most perioperative patients. Surgical and procedural stimuli produce nociception regardless of depth of sedation - and if that nociception is not addressed, it contributes to central sensitisation, increased anaesthetic requirements, prolonged recovery, and poorer outcomes. Pre-emptive analgesia - providing analgesic cover before the nociceptive stimulus occurs - is more effective than trying to manage pain after it is already established. Drug selection at the premedication stage is an important part of this.

Different drug classes produce analgesia through fundamentally different mechanisms. Opioids (methadone, morphine, fentanyl, buprenorphine, butorphanol) act primarily at mu, kappa, and delta opioid receptors within the central nervous system and peripherally. NSAIDs and paracetamol work through inhibition of cyclo-oxygenase enzymes and prostaglandin synthesis, targeting peripheral and spinal sensitisation rather than central pain processing. Alpha-2 agonists produce analgesia through receptors in the dorsal horn of the spinal cord as well as supraspinal sites. These mechanisms are genuinely complementary, which is why multimodal analgesia - combining drugs from different classes - is more effective than escalating doses of a single agent.

Dysphoria and Disinhibition

Dysphoria and disinhibition are properties on this list that we never intend to produce, and yet they are among the most commonly overlooked in drug selection discussions. Dysphoria refers to an unpleasant or distressing alteration in mental state - not simply sedation or excitation, but something more specifically aversive. Animals experiencing dysphoria may vocalise, appear agitated, have a glazed or distressed expression, pace, or exhibit repetitive behaviours. Crucially, these signs can be mistaken for inadequate sedation, leading to the instinct to give more drug - which in the case of some opioids, may worsen the dysphoria rather than resolve it.

Paradoxical disinhibition is a distinct but related phenomenon. Rather than an aversive alteration in mental state, it represents a loss of the normal inhibitory control over behaviour - the animal becomes more reactive, agitated, or uninhibited rather than calmer. Where dysphoria reflects a negative emotional experience, disinhibition reflects a failure of the expected sedative effect, with behavioural restraint removed rather than enhanced. Benzodiazepines are the most well-recognised cause in veterinary patients, particularly when given without concurrent sedation in otherwise healthy animals. The result can look superficially similar to dysphoria - a distressed, difficult-to-handle patient - but the underlying mechanism and the appropriate response differ.

Dysphoria is most commonly associated with opioids, and its likelihood is both drug- and dose-dependent. Not all opioids carry the same risk. It also has a meaningful species component - cats appear more sensitive to opioid-induced dysphoria than dogs, and individual variation within species is considerable.

The mechanism is not entirely clear, but kappa opioid receptor activity is thought to play a significant role. Drugs with higher kappa activity - butorphanol being a prominent example - carry a higher inherent risk of dysphoric effects. This is worth knowing because butorphanol is widely used in veterinary practice, and its dysphoric potential is not always prominently discussed.

The drugs in context

The following outlines the key pharmacological properties of commonly used perioperative drugs. Understanding what each drug reliably delivers - and what it does not - is the basis for building rational protocols.

Acepromazine (ACP)

Produces reliable, dose-dependent sedation. It does not reliably produce anxiolysis in the true pharmacological sense, does not provide analgesia, and has no meaningful dysphoria/disinhibition potential. Its value lies in sedation and in reducing anaesthetic requirements - it works well as part of a combination but should not be expected to address pain or anxiety as distinct clinical problems.

NSAIDs and paracetamol

Provide genuine analgesia with no sedation, no anxiolysis, and no dysphoria/disinhibition potential. They are purely analgesic at clinical doses. Because they work through a completely different mechanism to opioids and alpha-2 agonists, they add real analgesic value in combination without increasing CNS depression.

Midazolam and diazepam

Produce moderate sedation and good anxiolysis, with no analgesic effect. In that sense they appear to be a useful combination of properties - and in certain contexts, particularly in debilitated, geriatric, or critically ill patients, they are. The important caveat is their dysphoria/disinhibition potential, which is higher than is commonly appreciated and is a significant clinical consideration in otherwise healthy, younger animals.

The paradoxical response - where a patient becomes more agitated, disinhibited, or distressed rather than calmer - is well recognised with benzodiazepines and appears to be more likely when the patient's arousal level is already low, or when the drug is given without adequate concurrent sedation. In a healthy young dog or cat given midazolam alone, disinhibition rather than sedation is a common outcome. The animal is not in pain and is not simply under-sedated - the benzodiazepine has removed the normal inhibitory restraint on behaviour without providing the sedative depth needed to keep the patient manageable. This is why benzodiazepines are rarely used as sole premedicants in healthy patients, and why they reliably perform better when combined with an opioid or alpha-2 agonist that provides genuine sedative depth alongside them.

Their anxiolytic properties are real and valuable, particularly in the perioperative context - reducing the catecholamine-driven stress response and lowering anaesthetic requirements. Used appropriately, as part of a combination in a patient where their sedative limitations are accounted for, they earn their place. Used as a standalone agent in the wrong patient, they can make the situation considerably worse.

Medetomidine and dexmedetomidine

Provide excellent, reliable sedation alongside genuine anxiolysis and a degree of analgesia. Their dysphoria/disinhibition potential is low. As noted above, the sedation and analgesic dose-response curves differ - do not assume that a sedated alpha-2 patient is also well-analgesed. They provide very good synergy with opioids, which is why the combination is a standard of care in most protocols for higher-risk or more painful procedures.

Methadone

Produces moderate sedation and good analgesia. Like other opioids it does not contribute meaningfully to anxiolysis, which is worth remembering when the patient's anxiety level is a primary concern. Its dysphoria/disinhibition potential is present but modest compared to some other opioids, and it is widely regarded as one of the better balanced opioids for perioperative use in veterinary patients - which likely explains its popularity as a premedication.

Morphine

Produces good sedation and good analgesia. As with opioids generally, it does not contribute meaningfully to anxiolysis. It carries significant dysphoria/disinhibition potential, and this is dose-dependent - lower doses in the clinical range carry less risk than higher doses. Species and individual variation in dysphoria response to morphine are considerable.

Fentanyl

Produces good sedation and good analgesia, without meaningful anxiolysis. Like morphine, it carries significant dysphoria/disinhibition potential at higher doses. Its short duration of action when given as a single injection means it is more commonly used as an intraoperative infusion than as a premedicant, but its properties are worth understanding in that context.

Butorphanol

Occupies an interesting and sometimes misunderstood position. It produces good sedation, but its analgesic efficacy is genuinely modest - and importantly, as an agonist-antagonist it has a ceiling effect on analgesia and will partially antagonise the analgesic effects of other opioids if given concurrently. Like other opioids it does not contribute meaningfully to anxiolysis. Its dysphoria/disinhibition potential is moderate to significant - higher than is often appreciated. For patients where the primary indication is sedation and analgesia requirements are low, it has a role. For painful patients, it is often the wrong choice.

Buprenorphine

Provides mild to moderate sedation and moderate analgesia, without meaningful anxiolysis. Its dysphoria/disinhibition potential is significant and somewhat underappreciated in clinical practice. As a partial mu agonist with high receptor affinity, it can be difficult to reverse with naloxone when dysphoria does occur, which makes patient selection and dose selection important considerations.

Putting it together - a framework for selection

The question to ask at the point of drug selection is not "what do we usually give?" but rather "what does this specific patient need, and what is the risk profile that matters here?"

A fractious, highly anxious but otherwise healthy cat undergoing a routine procedure has different needs to a painful trauma patient, which has different needs to an aged dog with cardiovascular compromise presenting for elective dental work. Sedation, anxiolysis, and analgesia all contribute to a smooth perioperative course - but they are not interchangeable, and the drugs that deliver them are not equivalent.

The most rational approach is to identify which of these properties the patient genuinely needs, match those needs to drugs that reliably deliver the relevant properties at clinical doses, and then consider the dysphoria/disinhibition risk in the context of species, dose, and individual patient factors. Most good protocols achieve this through combination - using two or three complementary drugs that together cover sedation, anxiolysis, and analgesia without relying on any single drug to do all three.